Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- INBX
- Price
- 11.61
- Stock movement up
- +0.29 (2.56%)
- Company name
- Inhibrx Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 168.07M
- Ent value
- 15.83M
- Price/Sales
- 96.92
- Price/Book
- 0.94
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 0.10
- Forward P/E
- -
- PEG
- -
- EPS growth
- 36.45%
- 1 year return
- -66.80%
- 3 year return
- -21.42%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-11
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
INBX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 0.10 |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | 0.10 |
| EV to EBITDA | 0.01 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 96.92 |
| Price to Book | 0.94 |
| EV to Sales | 9.13 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 14.48M |
| EPS (TTM) | 106.14 |
| FCF per share (TTM) | -13.80 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 1.73M |
| Gross profit (TTM) | 601.00K |
| Operating income (TTM) | -369.81M |
| Net income (TTM) | 1.64B |
| EPS (TTM) | 106.14 |
| EPS (1y forward) | -11.03 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 34.66% |
| Operating margin (TTM) | -21326.93% |
| Profit margin (TTM) | 94684.72% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 196.33M |
| Net receivables | 455.00K |
| Total current assets | 207.45M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 222.56M |
| Accounts payable | 12.37M |
| Short/Current long term debt | 1.83M |
| Total current liabilities | 44.09M |
| Total liabilities | 44.09M |
| Shareholder's equity | 178.47M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -207.51M |
| Capital expenditures (TTM) | 6.02M |
| Free cash flow (TTM) | -213.53M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 919.96% |
| Return on Assets | 737.70% |
| Return on Invested Capital | 910.60% |
| Cash Return on Invested Capital | -118.43% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 11.26 |
| Daily high | 11.77 |
| Daily low | 10.80 |
| Daily Volume | 103K |
| All-time high | 50.00 |
| 1y analyst estimate | 15.00 |
| Beta | 2.88 |
| EPS (TTM) | 106.14 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| INBX | S&P500 | |
| Current price drop from All-time high | -76.78% | -12.89% |
| Highest price drop | -82.96% | -56.47% |
| Date of highest drop | 14 Jun 2022 | 9 Mar 2009 |
| Avg drop from high | -49.26% | -11.07% |
| Avg time to new high | 69 days | 12 days |
| Max time to new high | 1084 days | 1805 days |
COMPANY DETAILS
Marketcap
168.07M
Marketcap category
Small-cap
Description
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
Employees
166
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner